The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picks3i Group Regulatory News (III)

Share Price Information for 3i Group (III)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2,879.00
Bid: 2,875.00
Ask: 2,877.00
Change: 36.00 (1.27%)
Spread: 2.00 (0.07%)
Open: 2,862.00
High: 2,886.00
Low: 2,850.00
Prev. Close: 2,843.00
III Live PriceLast checked at -
3i Group is an Investment Trust

To provide its shareholders with quoted access to private equity and infrastructure returns, its main focus is on making quoted and unquoted equity and/ or debt investments in businesses and funds in Europe, Asia and the Americas.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Action Capital Markets Seminar & portfolio update

21 Mar 2024 07:00

RNS Number : 7017H
3i Group PLC
21 March 2024
 

 

21 March 2024

 

3i Group plc

Action Capital Markets Seminar and portfolio update

 

3i Group plc ("3i", or "the Group") will be holding a capital markets seminar this morning, involving presentations from the management team of Action, our largest portfolio company. The seminar will include a presentation on Action's results and strategy, as well as a separate presentation focused on Action's sustainability programme. A live webcast of the seminar will take place at 10:00 (UK time), with the sustainability session starting at 12:30 after a short break, and expected to end by 13:15. To register for the webcast, please visit https://www.3i.com/investor-relations. An on-demand webcast of the seminar will also be available by the end of the day.

 

As disclosed in our Q3 performance update, in its 2023 financial year Action generated net sales of ?11,324 million and operating EBITDA of ?1,615 million, 28% and 34% respectively higher than in 2022. Like-for-like sales growth was 16.7% and the business added 303 stores in the year. Operating leverage and good cost discipline were the main drivers behind the increased EBITDA margin of 14.3%.

 

Action has seen a strong start to 2024 across all its geographies. In the period to the end of week 11, net sales were ?2.5 billion, 21% ahead of the same period in 2023. Like-for-like sales growth in the first 11 weeks of the year (which, compared to the same period last year, had one fewer trading day) was 9.6%, with growth in transactions accounting for over 100% of the strong performance. Cash and cash equivalents as at 17 March 2024 was ?1,077 million. The business has added 32 stores in the year to date, including Action's first two stores in Portugal. Action is planning to make another dividend payment to shareholders in the last week of March. More details on Action's performance will be available in the presentation.

 

We have also recently completed our semi-annual portfolio company review meetings. The rest of the 3i portfolio continues to demonstrate overall resilience with the majority of companies showing good momentum into 2024. Our full year results will be published in May.

 

- Ends -

 

For further information, contact:

 

3i Group plc

 

Silvia Santoro

Investor enquiries

 

Kathryn van der Kroft

Media enquiries

 

 

 

Tel: +44 20 7975 3258

Email: silvia.santoro@3i.com

 

Tel: +44 20 7975 3021

Email: kathryn.vanderkroft@3i.com

 

Notes to editors:

 

About 3i Group

3i is a leading international investment manager focused on mid-market Private Equity and Infrastructure. Our core investment markets are northern Europe and North America.

 

For further information, please visit: www.3i.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCURVURSNUOUUR
Date   Source Headline
2nd Apr 20248:01 amRNSPortfolio Update
28th Mar 20241:02 pmRNSTotal Voting Rights
28th Mar 20241:00 pmRNSDirector/PDMR Shareholding
21st Mar 20241:53 pmRNSDirector/PDMR Shareholding
21st Mar 20247:00 amRNSAction Capital Markets Seminar & portfolio update
1st Mar 202410:11 amRNSDirector/PDMR Shareholding
29th Feb 20244:21 pmRNSTotal Voting Rights
1st Feb 20247:00 amRNS3i Group plc - Q3 performance update
31st Jan 20244:17 pmRNSTotal Voting Rights
31st Jan 20244:14 pmRNSDirector/PDMR Shareholding
4th Jan 20243:36 pmRNSTotal Voting Rights
4th Jan 20243:35 pmRNSDirector/PDMR Shareholding
3rd Jan 202412:00 pmRNSPortfolio Update
8th Dec 20231:11 pmRNSBlock listing Interim Review
30th Nov 20234:55 pmRNSTotal Voting Rights
30th Nov 20234:51 pmRNSDirector/PDMR Shareholding
23rd Nov 202311:11 amRNSDirector Declaration
20th Nov 20239:13 amRNSDirector Declaration
9th Nov 20232:29 pmRNSDirector/PDMR Shareholding
9th Nov 202311:49 amRNSDoc re. Half Yearly Report 2023
9th Nov 20237:00 amRNSHalf-year Report
31st Oct 20233:29 pmRNSTotal Voting Rights
31st Oct 20233:27 pmRNSDirector/PDMR Shareholding
2nd Oct 202312:58 pmRNSDirector/PDMR Shareholding
2nd Oct 202310:36 amRNSPortfolio Update
28th Sep 20231:35 pmRNSDirector/PDMR Shareholding
20th Sep 20237:00 amRNSUpdate on portfolio and Capital Markets Seminar
12th Sep 202310:43 amRNSDirector/PDMR Shareholding
4th Sep 202310:41 amRNSDirector/PDMR Shareholding
31st Aug 20233:56 pmRNSTotal Voting Rights
31st Aug 20233:52 pmRNSDirector/PDMR Shareholding
1st Aug 202311:40 amRNSDirector/PDMR Shareholding
31st Jul 20234:31 pmRNSTotal Voting Rights
31st Jul 20234:27 pmRNSDirector/PDMR Shareholding
20th Jul 20237:00 amRNSFY2024 Q1 performance update
3rd Jul 202310:25 amRNSPortfolio Update
30th Jun 20233:43 pmRNSTotal Voting Rights
30th Jun 20233:37 pmRNSDirector/PDMR Shareholding
30th Jun 202311:01 amRNSDirector/PDMR Shareholding
29th Jun 20235:00 pmRNSDirectorate Change
29th Jun 20233:46 pmRNSDirector/PDMR Shareholding
29th Jun 20233:31 pmRNSDoc re. AGM Resolutions
29th Jun 20233:30 pmRNSResult of AGM
29th Jun 20237:00 amRNSAGM and portfolio update
28th Jun 20232:34 pmRNSDirector/PDMR Shareholding
12th Jun 20232:33 pmRNSPublication of a Prospectus
9th Jun 20239:44 amRNSBlock listing Interim Review
8th Jun 20232:51 pmRNSDirector/PDMR Shareholding
7th Jun 202311:21 amRNSDTR 6.3.5
5th Jun 20233:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.